SCHEMBL4508728

SCHEMBL4508728

CCN1C(=O)C(C)(C)c2cc3nc(-c4n[nH]c5cc(-c6ccc(C(=O)O)cc6)ccc45)[nH]c3cc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 9/20 0.51
PRKCZ Q05513 6/20 0.51
AURKA O14965 2/20 0.51
AURKB Q96GD4 2/20 0.51
JAK2 O60674 3/20 0.42
JAK1 P23458 3/20 0.42
TYK2 P29597 3/20 0.42
JAK3 P52333 3/20 0.42
CDK4 P11802 3/20 0.42
CCNA2 P20248 3/20 0.42
CCND1 P24385 3/20 0.42
CCND3 P30281 3/20 0.42
MPL P40238 1/20 0.42
FLT3 P36888 2/20 0.41
CHEK1 O14757 5/20 0.40
MAP2K4 P45985 2/20 0.40
MAPK1 P28482 1/20 0.40
MAPK6 Q16659 1/20 0.40
SRC P12931 1/20 0.40
KDR P35968 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4501953 0.93 CDK2 (0.51) CDK2PRKCZAURKAAURKBJAK2
SCHEMBL4500435 0.93 AURKA (0.54) CDK2PRKCZAURKAAURKBJAK2
SCHEMBL4506484 0.92 AURKA (0.54) CDK2PRKCZAURKAAURKBJAK2
SCHEMBL4508446 0.89 CHEK1 (0.53) CDK2PRKCZAURKAAURKBJAK2
SCHEMBL4497871 0.88 AURKA (0.54) CDK2AURKAAURKBFLT3CHEK1
SCHEMBL4517359 0.88 AURKA (0.51) CDK2PRKCZAURKAAURKBJAK2
SCHEMBL4889244 0.87 CHEK1 (0.55) CDK2PRKCZAURKAAURKBJAK2
SCHEMBL4504819 0.87 AURKA (0.52) CDK2PRKCZAURKAAURKBJAK2
SCHEMBL4505475 0.86 AURKA (0.54) CDK2PRKCZAURKAAURKBJAK2
SCHEMBL4510663 0.85 AURKA (0.51) CDK2AURKAAURKBJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291968-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS GEORGES GUY 2009-11-26 US claimed
US-20090291968-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS GEORGES GUY 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291968-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS CYP3A43, CYP3A5, CYP3A7 CDK2 759/4885PRKCZ 2285/4885AURKA 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.